Zim Laboratories
Healthcare
ZIMLAB NSE
₹134.43 −7.96 (−5.59%)
- P/E
- 176.88
Close 4 Nov 2026 ₹134.43 +63.61 +89.8% 1Y
Start ₹70.82
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 4.76%
- Debt to Equity
- 0.43
- EPS (TTM)
- ₹0.76
- Book Value
- ₹54.77
- Market Cap
- —
- P/E (TTM)
- 176.88
- P/B
- 2.45
- ROE
- 1.59%
- Dividend Yield
- 0.00%
- EBITDA
- ₹41.40 Cr
- 52W High
- ₹159.81
- 52W Low
- ₹59.31
- Day Range
- ₹133.05 – ₹143.80
- Volume
- 1,18,834
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Zim Laboratories (this company) | ₹134.43 | 176.88 | ₹751 Cr | 2.45 | 0.00% | 1.59% | 4.76% | ₹397 Cr | ₹4 Cr |
| Median 8 companies | ₹1,587.70 | 58.71 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
46 Average
Data confidence 100/100
Category scores
- Quality
- 47
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 36
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 30
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 29
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company's working capital requirements have reduced from 52.8 days to 41.0 days
Weaknesses
7- Stock is trading at 2.76 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.03% over past five years.
- Promoter holding is low: 30.4%
- Company has a low return on equity of 4.54% over last 3 years.
- Earnings include an other income of Rs.10.9 Cr.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 7 | 7 | 5 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Bearish
Bearish
7
Neutral
7
Bullish
5
Moving Averages
Neutral
Bearish
5
Neutral
0
Bullish
5
Key readings
- RSI (14)
- 48.13
- Neutral
- MACD (12,26,9)
- 0.10
- Bearish
- SMA (50)
- 134.96
- Bearish
- SMA (200)
- 103.39
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +3.35% |
|---|---|
| 5Y | +4.03% |
| 3Y | −2.13% |
| 1Y | −1.32% |
| TTM | +7.55% |
Net profit
| 10Y | +1.84% |
|---|---|
| 5Y | −3.04% |
| 3Y | −37.00% |
| 1Y | −50.00% |
| TTM | −60.60% |
Operating cash flow
| 10Y | +8.56% |
|---|---|
| 5Y | +9.34% |
| 3Y | +9.58% |
| 1Y | +21.95% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −3.13 pp |
|---|---|
| 5Y | −5.01 pp |
| 3Y | −5.01 pp |
| 1Y | −3.59 pp |
| TTM | −3.72 pp |
Revenue by year
| Mar 2017 | ₹235 Cr |
|---|---|
| Mar 2018 | ₹273 Cr |
| Mar 2019 | ₹335 Cr |
| Mar 2020 | ₹278 Cr |
| Mar 2021 | ₹307 Cr |
| Mar 2022 | ₹333 Cr |
| Mar 2023 | ₹399 Cr |
| Mar 2024 | ₹367 Cr |
| Mar 2025 | ₹379 Cr |
| Mar 2026 | ₹374 Cr |
Net profit by year
| Mar 2017 | ₹19.00 Cr |
|---|---|
| Mar 2018 | ₹19.00 Cr |
| Mar 2019 | ₹15.00 Cr |
| Mar 2020 | ₹3.00 Cr |
| Mar 2021 | ₹7.00 Cr |
| Mar 2022 | ₹15.00 Cr |
| Mar 2023 | ₹24.00 Cr |
| Mar 2024 | ₹17.00 Cr |
| Mar 2025 | ₹12.00 Cr |
| Mar 2026 | ₹6.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.44 | 85.83 | 96.29 | 118 | 81.82 | 92.14 | 96.33 | 109 | 71.76 | 88.71 | 109 | 105 | 94.18 |
| Expenses | 62.62 | 76.5 | 84.75 | 102 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating Profit | 4.82 | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.6 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 7.15% | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.6% |
| Other Income | 1.12 | 1.42 | 1.11 | 1.53 | 1 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.7 | 6.16 | 0.99 |
| Interest | 1.73 | 1.22 | 1.7 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.3 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 4.03 | 4.09 | 3.94 | 3.91 | 4.94 | 5 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.1 | 5.37 |
| PBT | 0.19 | 5.44 | 7.01 | 11 | 1.23 | 2.96 | 5.7 | 8.11 | −2.43 | −0.34 | 6.05 | 4.94 | −5.57 |
| Tax % | −22.22% | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30% | 39.7% | −22.63% | 23.53% | 27.27% | 24.29% | −28.01% |
| Net Profit | 0.23 | 4.15 | 4.78 | 8.09 | 0.9 | 2.38 | 4 | 4.88 | −1.87 | −0.42 | 4.4 | 3.74 | −4.02 |
| EPS (₹) | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1 | −0.38 | −0.09 | 0.9 | 0.7 | −0.75 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Expenses | 278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 369 |
| Operating Profit | −12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | −4.4% | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 11% | 12% | 8% | 7% |
| Other Income | 2 | −2 | 5 | 9 | 2 | 5 | −3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 20 |
| PBT | −27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 5 |
| Tax % | −19% | 5% | −6% | 23% | 30% | −4600% | 28% | 31% | 31% | 27% | 32% | 29% | — |
| Net Profit | −22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS (₹) | — | — | — | — | 3.17 | 0.68 | 1.5 | 2.99 | 5.01 | 3.54 | 2.5 | 1.09 | 0.76 |
| Div. Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
| Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings | 93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 |
| Other Liabilities | 78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 |
| Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed Assets | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 |
| CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Investing | — | −12 | −7 | −26 | −21 | −18 | −6 | −14 | −35 | −73 | −40 | −55 |
| Financing | — | −10 | −25 | −10 | −15 | −3 | −26 | −33 | 1 | 60 | −9 | 28 |
| Net Cash Flow | — | 0 | 0 | 1 | −1 | 1 | 0 | 2 | 3 | 3 | −8 | 23 |
| Free Cash Flow | — | 9 | 24 | 8 | 15 | 3 | 25 | 34 | 1 | −57 | 1 | 11 |
| CFO/OP | — | 77 | 109 | 117 | 85 | 119 | 83 | 121 | 86 | 46 | 92 | 177 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 120 | 137 | 119 | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory Days | 93 | 87 | 108 | 134 | 126 | 144 | 125 | 171 | 99 | 173 | 188 | 207 |
| Days Payable | 129 | 109 | 137 | 172 | 165 | 168 | 149 | 185 | 107 | 133 | 151 | 161 |
| Cash Conversion Cycle | 75 | 99 | 108 | 81 | 63 | 65 | 62 | 85 | 79 | 140 | 140 | 152 |
| Working Capital Days | 38 | 34 | 54 | 37 | 39 | 46 | 49 | 67 | 67 | 57 | 60 | 41 |
| ROCE % | — | 13% | 14% | 14% | 15% | 5% | 11% | 12% | 17% | 10% | 8% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zim Laboratories insights
72 extracted metrics across FY10–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT
- Q1 FY26 concall · Aug 2025Transcript PPT
- 6 Aug 2026
- 19 May 2026
- 8 Oct 2026
- 17 Feb 2026
- 3 Oct 2025
- 19 Nov 2024
- 8 Oct 2024
- General announcements 31 Oct 2026
- General announcements 16 Oct 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Zim Laboratories
What does Zim Laboratories Ltd do?
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India
Where is Zim Laboratories Ltd (ZIMLAB) listed?
Zim Laboratories Ltd trades as ZIMLAB on the NSE and under code 541400 on the BSE.
Which sector does Zim Laboratories Ltd belong to?
Zim Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Zim Laboratories Ltd?
Zim Laboratories Ltd trades at a PE ratio of 176.88 as of 4 Nov 2026, on earnings per share of ₹0.76, against a book value of ₹54.77 per share.
What is the 52-week high and low of Zim Laboratories Ltd?
Over the last 52 weeks Zim Laboratories Ltd has traded between ₹59.31 and ₹159.81 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Zim Laboratories Ltd?
Zim Laboratories Ltd reported a return on equity of 1.59%. Its debt-to-equity ratio is 0.43.
Company Information
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZIMLAB.md for Zim Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.